Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of brigatinib with carboplatin + pemetrexed vs brigatinib alone in first-line advanced ALK-positive NSCLC
2021-002567-22Phase 2Active
- Sponsor
- IFCT
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brigatinib in ALK-positive non-small cell lung cancer (2 arms), sponsored by IFCT. Primary endpoint: Progression-Free Survival at 12 months (investigator assessment). Started Oct 2021; status: active.
02
Drugs
brigatinib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on 2021-002567-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002567-22.